INTRODUCTION
============

Angiogenesis is the physiological process through which new blood vessels are generated from pre-existing vessels; it is not only necessary for embryologic development, normal growth, and tissue repair, but is also involved in pathological processes such as tumor growth ([@b1-bmb-50-384]). Angiogenesis is controlled by a fine balance between pro- and anti-angiogenic factors ([@b2-bmb-50-384]), with endothelial cells (ECs) being key regulators of this process. Pro-angiogenic factors, among which the vascular endothelial growth factor A (VEGF-A) is the most potent regulator of angiogenesis, exert coordinated control over multiple EC phenotypic behaviors such as migration, proliferation, differentiation, and polarity ([@b3-bmb-50-384]). During the angiogenic process, VEGF-A binds to its cognate receptor, VEGFR2 (VEGF receptor-2; also termed KDR and Flk-1), activating the elements of the angiogenic signaling cascade, such as mitogen-activated protein kinases (MAPKs) and the endothelial nitric oxide synthase (eNOS), in ECs ([@b1-bmb-50-384], [@b2-bmb-50-384], [@b4-bmb-50-384]). Abnormal angiogenesis caused by EC dysfunction has been involved in cancer and pathological conditions associated with vessel deterioration, such as diabetic wound healing, infectious diseases, and pulmonary hypertension ([@b5-bmb-50-384]--[@b9-bmb-50-384]).

Accumulating evidence indicates an important role for Nogo-B receptor (NgBR) signaling and the expression level of this receptor in angiogenesis ([@b10-bmb-50-384]--[@b13-bmb-50-384]). NgBR is a transmembrane receptor protein that has been identified as a Nogo-B-binding protein and is essential for the Nogo-B-mediated chemotaxis of ECs and their organization into tubes ([@b10-bmb-50-384]). In addition, NgBR is necessary for VEGF-induced angiogenesis in ECs, as the genetic knockdown of *Nogo-B* or *NgBR* in a zebrafish model leads to defective intersomitic vessel formation during embryonic angiogenesis ([@b12-bmb-50-384]), with the defects being more severe in the case of *NgBR* knockdown. More recently, it was reported that endothelial-specific *NgBR* knockout leads to early embryonic lethality in mice due to defects in vascular development and NgBR participates in this process through a Nogo-B-independent mechanism ([@b14-bmb-50-384]). These studies indicate that NgBR is involved in Nogo-B-independent angiogenic signaling pathways. Overall, despite the fact that the Nogo-B-NgBR axis has been found to be important in EC angiogenesis, our understanding of the role of NgBR in Nogo-B-independent angiogenic processes remains incomplete. Thus, the elucidation of the mechanisms underlying the regulation of angiogenic processes induced independently of Nogo-B, e.g., by the VEGF-NgBR axis, might be important. In addition, the dysregulation of NgBR expression leads to a wide array of diseases, including IPH, pediatric epilepsy, and cancer ([@b11-bmb-50-384], [@b15-bmb-50-384]--[@b18-bmb-50-384]), which, combined with the involvement of this receptor in the regulation of angiogenic phenotypes in ECs, indicates that the modulation of NgBR expression might prove useful as a new therapeutic approach for diseases caused by abnormal angiogenesis.

This study sought to investigate the regulatory mechanisms underlying the VEGF-NgBR axis-mediated angiogenesis. We report a novel miR-26a-mediated molecular mechanism that plays a critical role in VEGF-mediated angiogenesis by regulating the expression of NgBR.

RESULTS
=======

VEGF upregulates NgBR and reduces miR-26a expression in ECs
-----------------------------------------------------------

To investigate the effect of VEGF on NgBR expression in ECs, human umbilical vein endothelial cells (HUVECs) were stimulated with VEGF. Both the mRNA and the protein expression of NgBR increased, suggesting that VEGF signaling regulates NgBR expression and providing clues to the molecular mechanism of VEGF-NgBR axis-mediated angiogenesis ([Fig. 1A and B](#f1-bmb-50-384){ref-type="fig"}). The next step was the identification of the mechanisms underlying the induction of NgBR expression by VEGF stimulation in ECs. We first examined the possibility that microRNAs (miRNAs) acted as post-transcriptional regulators of the VEGF-induced increase in NgBR expression. The algorithms of Targetscan were used to identify miRNAs that potentially target the 3′-untranslated region (3′-UTR) of the *NgBR* mRNA. The analysis predicted that miR-26a, a miRNA with highly conserved seed sequences, may bind to the 3′-UTR of *NgBR* at two binding sites, and could thus be a potential regulator of NgBR expression ([Fig. 1C](#f1-bmb-50-384){ref-type="fig"}). We next investigated whether the expression of miR-26a is inversely correlated with that of NgBR after stimulation of HUVECs with VEGF, and found that miR-26a expression was significantly lower in VEGF-treated HUVECs than in controls ([Fig. 1D](#f1-bmb-50-384){ref-type="fig"}), suggesting a possible involvement of miR-26a in the mechanism underlying the induction of NgBR expression in response to VEGF.

MiR-26a regulates VEGF signaling by directly targeting NgBR
-----------------------------------------------------------

To evaluate whether miR-26a is indeed involved in the regulation of NgBR expression, we first determined the effects of miR-26a overexpression on NgBR expression in HUVECs. Results showed that the overexpression of miR-26a in HUVECs led to a significant downregulation of both the mRNA and protein levels of NgBR ([Fig. 2A and B](#f2-bmb-50-384){ref-type="fig"}, respectively). Next, to determine whether miR-26a regulates NgBR expression via binding directly to the *NgBR* 3′-UTR, we examined the effects of miR-26a overexpression in HEK293T cells transfected with a luciferase reporter construct containing either the wild-type or a mutant *NgBR* 3′-UTR. Results showed a significant reduction in the luciferase activity of the *NgBR* 3′-UTR-wt construct, whereas the activity of the *NgBR* 3′-UTR-mt construct was not affected ([Fig. 2C](#f2-bmb-50-384){ref-type="fig"}). Taken together, these results suggest that miR-26a directly regulates NgBR expression in HUVECs. It was also evaluated whether the perturbation of miR-26a expression affected the phosphorylation of eNOS, which is one of the main downstream targets of VEGF-induced NgBR signaling in ECs and plays a key role in the regulation of angiogenesis. First, we performed a time course for the phosphorylation of eNOS in VEGF-treated HUVECs. It was found that VEGF led to maximum eNOS phosphorylation after 5--15 min and then started to decline, reaching the basal level after another 15 min, i.e., 20--30 min after stimulation ([Fig. 2D](#f2-bmb-50-384){ref-type="fig"}). We next examined whether reducing NgBR expression by NgBR knockdown or miR-26a overexpression resulted in altered eNOS activity in VEGF-stimulated HUVECs and found that both manipulations reduced VEGF-induced eNOS phosphorylation ([Fig. 2E and F](#f2-bmb-50-384){ref-type="fig"}). Given that eNOS catalyzes the production of NO, a molecule involved in angiogenesis through its role as an important downstream mediator of angiogenic factors such as VEGF, we also assessed NO levels by measuring DAF fluorescence. VEGF significantly increased DAF fluorescence, an effect that was completely abrogated by concurrent miR-26a overexpression ([Fig. 2G](#f2-bmb-50-384){ref-type="fig"}). Overall, these findings suggest an important role for the miR-26a-NgBR-eNOS signaling pathway in VEGF-induced angiogenesis.

NgBR inhibition attenuates VEGF-induced migration in ECs
--------------------------------------------------------

Given the angiogenic properties of VEGF in ECs and its ability to upregulate NgBR expression, migration assays were utilized to investigate the role of NgBR in VEGF-induced angiogenesis. As shown in [Fig. 3A](#f3-bmb-50-384){ref-type="fig"}, VEGF significantly induced HUVEC migration, an effect that was completely abrogated when NgBR was knocked down. The effectiveness of the knockdown was validated by determining the mRNA and protein levels of NgBR. Results showed significant reductions in both of them (roughly 80% and 40%, respectively; [Fig. 3B and C](#f3-bmb-50-384){ref-type="fig"}). These findings indicate a key role for NgBR signaling in the regulation of VEGF-mediated angiogenesis.

MiR-26a impairs pro-angiogenic phenotypes in ECs
------------------------------------------------

To characterize the role of endothelial miR-26a in angiogenesis, we first assessed the effects of miR-26a overexpression on the proliferation and the migratory ability of HUVECs cultured in complete endothelial cell medium and found that it significantly reduced both properties ([Fig. 4A and B](#f4-bmb-50-384){ref-type="fig"}), indicating that miR-26a exerts a potential anti-angiogenic function in HUVECs stimulated by complete media. The finding that miR-26a directly regulates NgBR expression led us to investigate the effects of miR-26a overexpression on VEGF-induced angiogenesis by performing proliferation, migration, and tube formation assays in HUVECs. As expected, the overexpression of miR-26a significantly reduced VEGF-induced HUVEC proliferation, migration, and tube formation ([Fig. 4C--E](#f4-bmb-50-384){ref-type="fig"}, respectively). Taken together, the results of this study suggest an important role for the miR-26a-NgBR signaling pathway in VEGF-induced angiogenesis in ECs.

DISCUSSION
==========

Although NgBR-mediated angiogenesis has drawn much attention, only a few studies have examined the role of NgBR in this process, in particular with regard to the underlying molecular mechanism regulating NgBR expression during angiogenesis and the mechanistic role of NgBR in Nogo-B-independent angiogenesis, such as the one mediated by the VEGF-NgBR axis. This study demonstrated the essential role of miR-26a in regulating VEGF-induced NgBR expression and, by extension, the angiogenic effects of this protein. These findings can be summarized into four major conclusions: (i) NgBR and miR-26a expression levels are reversely correlated in VEGF-stimulated HUVECs. (ii) NgBR is a direct target of miR-26a. (iii) miR-26a inhibits VEGF-induced angiogenic phenotypes in HUVECs. (iv) miR-26a inhibits VEGF-induced eNOS phosphorylation and NO production.

Previous studies have demonstrated that NgBR plays an important role in various physiological and pathological processes, such as angiogenesis, development, and tumor growth ([@b11-bmb-50-384]--[@b17-bmb-50-384]). Most of these studies focused on investigating the effects of NgBR overexpression or knockdown and simply determining the NgBR expression levels *in vitro* or *in vivo*. Given that the control of NgBR expression is critical to the regulation of angiogenesis, the molecular mechanism underlying this regulation in ECs is important for assessing the angiogenic process. In recent years, much attention has been paid to the role of miRNAs in angiogenesis, particularly VEGF-targeting or VEGF-responsive miRNAs. For example, miR-16, the miR-424/503 cluster, miR-126, and miR-497 are anti-angiogenic miRNAs that directly target the *VEGF* mRNA in ECs and cancer cells ([@b19-bmb-50-384]--[@b22-bmb-50-384]), whereas the miR-17--92 cluster, miR-16, and miR-424 respond to VEGF stimulation and modulate EC angiogenic responses ([@b19-bmb-50-384], [@b23-bmb-50-384]).

MiR-26a is highly expressed in ECs ([@b24-bmb-50-384]) and is known to be a key regulator of EC functions such as angiogenesis and apoptosis ([@b18-bmb-50-384], [@b25-bmb-50-384], [@b26-bmb-50-384]). Previous studies have shown that the ectopic expression of miR-26a leads to the inhibition of angiogenesis, whereas the administration of miR-26a inhibitors induces the angiogenic properties of ECs by activating BMP/SMAD1 signaling ([@b26-bmb-50-384], [@b27-bmb-50-384]). Furthermore, miR-26a exerts anti-apoptotic activity by directly targeting TRPC6 in ECs ([@b25-bmb-50-384]). Taken together, all these evidences suggest that the modulation of miR-26a may represent a new therapeutic option for vascular diseases. However, the roles of endothelial miR-26a in VEGF-mediated angiogenesis had not been determined. This study is the first to reveal the role of miR-26a in VEGF-induced angiogenesis and report on the molecular mechanisms involved in the regulation of NgBR expression. The current findings demonstrate that miR-26a reduces the expression of *NgBR* by directly targets NgBR reducing its expression, and the downregulation of miR-26a is the mechanism through which VEGF upregulates NgBR. Restoration of miR-26a expression results in NgBR downregulation, which in turn leads to the inhibition of the VEGF-induced angiogenic phenotypes including proliferation, migration, and the formation of capillary-like structures. In addition, this study demonstrated for the first time that miR-26a can regulate eNOS activity and NO production in VEGF-treated HUVECs. Since, as was also shown in this study, miR-26a targets NgBR expression, it may act as a key regulator of VEGF-induced NO production and, by extension, its angiogenic properties.

Overall, our research provides novel mechanistic insights into the angiogenesis signaling processes taking place in VEGF-stimulated endothelium. Specifically, it establishes a novel regulatory mechanism of VEGF-mediated angiogenesis, namely the ability of miR-26a to downregulate endothelial NgBR expression by directly targeting the 3′-UTR of the *NgBR* mRNA. Moreover, it proposes that the modulation of eNOS phosphorylation constitutes the downstream signaling mechanism regulated by the miR-26a-NgBR axis.

MATERIALS AND METHODS
=====================

Cell culture
------------

HUVECs were grown in endothelial cell growth medium-2 (EGM-2; Lonza, Basel, Switzerland) supplemented with 1% penicillin-streptomycin (WelGENE, Daegu, Korea) at 37°C in a 5% CO~2~ incubator. HEK293T cells were cultured in HyClone Dulbecco's modified Eagle's medium (DMEM; GE Healthcare Life Sciences, Marlborough, IL, USA) containing 10% fetal bovine serum (FBS; Gibco, Gaithersburg, MD, USA) and 1% penicillin-streptomycin. Both cell types were cultured to 70--80% confluency before each experiment.

Transfection
------------

Lipofectamine RNAimax and Lipofectamine 2000, both obtained from Invitrogen (Carlsbad, CA, USA), were used for miRNA and siRNA transfection following the manufacturer's instructions. The control miRNA and the miR-26a mimics used in *in vitro* transfections were also provided by Invitrogen. *NGBR* siRNAs (forward: 5′-GGAAAUACAUAGACCUACA-3′, reverse: 5′-UGUAGGUCUAUGUAUUUCC-3′) were synthesized from Genolution (Seoul, Korea). Stealth RNAi (ST Pharm, Ansan, Korea) was used as the negative control siRNA.

RNA extraction and quantitative real-time PCR
---------------------------------------------

Total RNA was isolated using the miRNeasy RNA isolation kit (Qiagen, Hilden, Germany). Purified RNA was reverse-transcribed using the TaqMan miRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). For microRNA amplification, the qPCR Universal Master Mix II, no UNG (Applied Biosystems) was used and miR-26a was detected with Taqman probes. RNU6B and 18S RNA were used as internal controls for the quantification of miR-26a and the *NgBR* mRNA, respectively. The primers for the PCR amplification of *NgBR* mRNA and 18S rRNA amplification were the following: *NgBR* forward, 5′-AGAGCTGCTCAGGACTTTTGCC-3′; *NgBR* reverse, 5′-TGCTGTCCACAGGACCGAACTT-3′; *18S* forward, 5′-ACCCGTTGAACCCCATTCGTGA-3′; *18S* reverse, 5′-GCCT CACTAAACCATCCAATCGG-3′.

Western blotting
----------------

HUVECs were lysed with RIPA buffer (GenDEPOT, Barker, TX, USA) containing protease and phosphatase inhibitor cocktail (Roche, Basel, Switzerland). Protein quantification was performed using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, USA) and equal protein concentrations were boiled, loaded into SDS-polyacrylamide gels, electrophoresed, and transferred to polyvinyl difluoride membranes (Merck Millipore, Billerica, MA, USA). Blots were treated with primary antibodies against NgBR (1:2,000; Abcam, Cambridge, MA, USA), phospho-eNOS (Ser-1177) (1:2,000; \#612392; BD Bioscience, Franklin Lakes, NJ, USA), and GAPDH (1:5,000; \#2118; Cell Signaling Technology). For immunodetection and development, HRP-conjugated secondary antibodies (1:3,000, Cell Signaling Technology) and an enhanced chemiluminescence detection system (Thermo Fisher Scientific) were used.

Luciferase reporter assay
-------------------------

The human *NgBR* 3′-UTR (2,144 bp), including the predicted binding sites of the two miR-26a seed sequences, was cloned between the Not1 and XhoI sites of the psiCHECK2 vector (Promega, Fitchburg, WI, USA), upstream of the *Renilla* luciferase coding region. We also created a construct containing a mutated *NgBR* 3′-UTR in which the first miR-26a-binding site had been altered (TTACTTG to TTGACTG) using the Muta-DirectTM Site-Directed Mutagenesis Kit (iNtRON Biotechnology, Seongnam, Korea). HEK293T cells were transfected with a luciferase reporter construct (containing either the wild-type or the mutant *NgBR* 3′-UTR) and miRNA (either the miR-26a mimic or negative control miRNA) using lipofectamine 2000. Cells were lysed after a 48-h incubation period and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).

Tube formation assay
--------------------

HUVECs were seeded on 6-well plates and transfected with miR-26a mimics using RNAimax (Invitrogen). After 24 h, cells were trypsinized, counted, and seeded at 1.5 × 10^4^ cells/well in 48-well plates pre-coated with phenol-red free, growth factor reduced (GFR) Matrigel Matrix (BD Bioscience). For treatments of VEGF (R&D Systems, Minneapolis, MN, USA), it was suspended in EBM-2 medium and used at the concentration of 50 ng/ml. The formation of tube-like structures was observed every 2 h under an optical microscope at 40× magnification and quantified with the Image J software (Open Access, Public Domain).

Proliferation assay
-------------------

HUVECs were seeded at a density of 5 × 10^3^ cells/well in 96-well plates. Following overnight incubation, cells were transfected with 24 nM of miR-26a mimic. After 24 h, the EGM-2 complete medium was removed and replaced with starvation medium. After another 12 h, VEGF (50 ng/ml) was added to the medium. Following incubation for another 24 h, 20 μl of the WST-1 reagent was added to each well and incubated for 1 h. The absorbance was measured by a microplate reader at 450 nm with a background reference wavelength of 620 nm. For assessing the effects of treatment with miR-26a only, the WST-1 reagent was added 24 or 48 h after transfection.

Migration assay
---------------

HUVECs were seeded at a density of 2 × 10^5^ cells/well in 12-well plates. After 24 h, cells were transfected with miR-26a mimic at 24 nM or *NgBR* siRNA at 36 nM. Cells were scratched with a P-200 pipette tip and incubated in starvation medium containing 1% FBS. VEGF (50 ng/ml) was added after scratching. Cells were observed under an optical microscope at ×40 magnification and measured using ImageJ.

Nitric oxide measurement
------------------------

HUVECs were seeded in 6-well plates and transfected with miR-26a mimic at 24 nM. After 16 h, media were replaced by serum-free medium. VEGF (50 ng/ml) was added to the starved HUVECs for 15 minutes. Carefully (to avoid detachment), cells were stained with DAF-FM diacetate at 5 μM under dark at 37°C. After the removal of excess probe, the relative levels of intracellular NO were determined by measuring their fluorescence intensity under a fluorescence microscope.
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![VEGF upregulates NgBR and reduces miR-26a expression in HUVECs. (A) *NgBR* mRNA expression after treatment of HUVECs with VEGF. (B) NgBR protein expression after treatment of HUVECs with VEGF. (C) Predicted target sequences of miR-26a on the *NgBR* 3′-UTR. (D) Expression of miR-26a in response to VEGF as assessed by quantitative PCR. \*p \< 0.01, \*\*\*p \< 0.0001 compared to controls by unpaired two-tailed Student's *t*-test. Error bars, standard error of the mean.](bmb-50-384f1){#f1-bmb-50-384}

![MicroRNA-26a inhibits VEGF signaling by directly targeting the NgBR. (A) *NgBR* mRNA expression in response to the overexpression of miR-26a in HUVECs. (B) NgBR protein expression in response to the overexpression of miR-26a in HUVECs. (C) Luciferase activity after overexpression of miR-26a in HEK293T cells transfected with a reporter construct containing the wild-type (wt) and the mutant (mt) *NgBR* 3′-UTR. (D) Temporal changes in phosphorylation of eNOS of HUVEC cultures upon treatment with VEGF (50 ng/ml). (E) Phosphorylation of eNOS in response to VEGF (50 ng/ml) in HUVEC *NgBR* knockdown cultures or cultures transfected with negative control siRNA. (F) Phosphorylation of eNOS in response to VEGF (50 ng/ml) in HUVECs overexpressing miR-26a or non-overexpressing control cultures. (G) Measurement of NO formation in VEGF-untreated and VEGF (50 ng/ml)-treated HUVEC cultures, as well as in VEGF-treated cultures overexpressing miR-26a. \*\*p \< 0.001, \*\*\*p \< 0.0001 compared to controls by unpaired two-tailed Student's *t*-test. Error bars, standard error of the mean.](bmb-50-384f2){#f2-bmb-50-384}

![NGBR knockdown abrogates the VEGF-induced endothelial migration. (A) Cell migration assays after VEGF (50 ng/ml) treatment of HUVEC cultures transfected with *NgBR* siRNA or negative control siRNA. (B) *NgBR* mRNA expression in HUVEC cultures after *NgBR* knockdown. (C) NgBR protein expression in HUVECs after *NgBR* knockdown. \*\*p \< 0.001, \*\*\*p \< 0.0001 vs. controls, calculated by unpaired two-tailed Student's *t*-tests. Error bars, standard error of the mean.](bmb-50-384f3){#f3-bmb-50-384}

![MicroRNA-26a impairs pro-angiogenic phenotypes in HUVECs. (A) Relative HUVEC viability 24 h and 48 h after the overexpression of miR-26a. (B) HUVEC migratory ability 8 h after the overexpression of miR-26a. (C) Relative viability in response to VEGF (50 ng/ml) in HUVEC cultures overexpressing miR-26a or non-overexpressing control cultures. (D) Cell migration in response to VEGF (50 ng/ml) in HUVEC cultures overexpressing miR-26a or non-overexpressing control cultures. (E) Tube formation in response to VEGF (50 ng/ml) by HUVECs overexpressing miR-26a overexpression or non-overexpressing control cultures. \*p \< 0.01, \*\*p \< 0.001, \*\*\*p \< 0.0001 compared to controls by unpaired two-tailed Student's *t*-test. Error bars, standard error of the mean.](bmb-50-384f4){#f4-bmb-50-384}
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